Marshall Wace
JANX icon

Marshall Wace’s Janux Therapeutics JANX Stock Holding History

Marshall Wace’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
+32,734
New +$474K ﹤0.01% 2518
2025
Q1 		– Sell
-22,348
Closed -$1.2M – 2865
2024
Q4 		$1.2M Sell
22,348
-25,703
-53% -$1.36M ﹤0.01% 1653
2024
Q3 		$2.18M Buy
+48,051
New +$2.09M ﹤0.01% 1337

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace's JANX Position: Q2 2026 in Review

Marshall Wace opened a new position in Janux Therapeutics (JANX) in Q2 2026: 32,734 shares worth $503K. The stake represents ﹤0.01% of the portfolio and ranks #2518 among its holdings. This is a return to the name: Marshall Wace previously reported a position in JANX as recently as Q4 2024.

Marshall Wace first reported a position in JANX in Q3 2024 and has held it in 3 quarters since. The position peaked at $2.18M in Q3 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Marshall Wace held 32,734 shares of Janux Therapeutics worth $503K as of Q2 2026.
  • Janux Therapeutics was a new Marshall Wace position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2518 holding.
  • Marshall Wace first reported a position in Janux Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Marshall Wace's Janux Therapeutics position peaked at $2.18M in Q3 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.